^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-A2009

    i
    Other names: SHR-A2009
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4ms
    Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=350, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1/2 trial • Metastases
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2009 • adebrelimab (SHR-1316)
    7ms
    A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=270, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    Ameile (aumolertinib) • SHR-A2009 • adebrelimab (SHR-1316)
    7ms
    The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | N=172 --> 19
    Enrollment closed • Enrollment change • Metastases
    |
    SHR-A2009
    10ms
    Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors (ESMO 2023)
    Conclusions SHR-A2009 showed a tolerable safety profile and encouraging anti-tumor activity in pts with heavily pretreated advanced solid tumors. The trial is ongoing to assess SHR-A2009 at higher doses and in selected cancer types (NSCLC and other solid tumors).
    P1 data • Metastases
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 expression
    |
    SHR-A2009